(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.43%) $78.82
(0.32%) $2.20
(0.16%) $2 334.90
(0.28%) $27.69
(0.23%) $967.10
(0.03%) $0.929
(0.06%) $10.83
(0.04%) $0.796
(0.02%) $91.36
Live Chart Being Loaded With Signals
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally...
Stats | |
---|---|
本日の出来高 | 1.79M |
平均出来高 | 1.68M |
時価総額 | 0.00 |
EPS | £0.0264 ( 2020-09-29 ) |
Last Dividend | £5.46 ( 2021-12-02 ) |
Next Dividend | £0 ( N/A ) |
P/E | 0.410 |
ATR14 | £0 (0.00%) |
Clinigen Group PLC 相関
10 最も正の相関 | |
---|---|
ARE.L | 0.952 |
3USS.L | 0.942 |
3ULS.L | 0.939 |
XPD.L | 0.936 |
MNZS.L | 0.93 |
PBLT.L | 0.925 |
GAW.L | 0.91 |
GPH.L | 0.891 |
IGE.L | 0.878 |
AIBG.L | 0.876 |
10 最も負の相関 | |
---|---|
YGEN.L | -0.965 |
DNM.L | -0.942 |
ECHO.L | -0.941 |
FRG.L | -0.932 |
EXR.L | -0.932 |
3NGL.L | -0.931 |
SIXH.L | -0.925 |
GIF.L | -0.921 |
VCAP.L | -0.911 |
MAST.L | -0.911 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Clinigen Group PLC 財務諸表
Annual | 2021 |
収益: | £523.60M |
総利益: | £197.90M (37.80 %) |
EPS: | £0.233 |
FY | 2021 |
収益: | £523.60M |
総利益: | £197.90M (37.80 %) |
EPS: | £0.233 |
FY | 2020 |
収益: | £504.30M |
総利益: | £220.00M (43.62 %) |
EPS: | £0.103 |
FY | 2019 |
収益: | £456.90M |
総利益: | £182.30M (39.90 %) |
EPS: | £0.0400 |
Financial Reports:
No articles found.
Clinigen Group PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
First Dividend | £0.600 | 2013-03-06 |
Last Dividend | £5.46 | 2021-12-02 |
Next Dividend | £0 | N/A |
Payout Date | 2022-01-04 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | £45.62 | -- |
Avg. Dividend % Per Year | 0.20% | -- |
Score | 3.07 | -- |
Div. Sustainability Score | 9.57 | |
Div.Growth Potential Score | 2.52 | |
Div. Directional Score | 6.04 | -- |
Year | Amount | Yield |
---|---|---|
2013 | £0 | 0.00% |
2014 | £0 | 0.00% |
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £5.60 | 0.64% |
2019 | £6.70 | 0.91% |
2020 | £7.61 | 0.83% |
2021 | £7.61 | 1.09% |
2022 | £0 | 0.00% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
S32.L | Dividend Junior | 2023-09-14 | Semi-Annually | 9 | 1.97% | |
HLMA.L | Dividend Knight | 2023-07-13 | Semi-Annually | 32 | 0.43% | |
BAKK.L | Dividend Knight | 2023-09-14 | Annually | 7 | 4.28% | |
W7L.L | Dividend Knight | 2023-11-09 | Annually | 8 | 2.69% | |
MTVW.L | Dividend Knight | 2023-07-06 | Semi-Annually | 32 | 2.55% | |
DRX.L | Dividend Knight | 2023-08-24 | Semi-Annually | 19 | 2.48% | |
SMS.L | Dividend Knight | 2023-07-06 | Quarterly | 13 | 2.02% | |
ING.L | Dividend Knight | 2023-09-21 | Annually | 32 | 2.29% | |
BPCR.L | Dividend Knight | 2023-08-17 | Quarterly | 8 | 1.46% | |
PAF.L | Ex Dividend Knight | 2023-11-30 | Annually | 16 | 1.80% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0579 | 1.500 | 8.84 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0284 | 1.200 | 9.05 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0679 | 1.500 | -0.357 | -0.535 | [0.1 - 1] |
payoutRatioTTM | 0.333 | -1.000 | 6.67 | -6.67 | [0 - 1] |
currentRatioTTM | 1.752 | 0.800 | 6.24 | 4.99 | [1 - 3] |
quickRatioTTM | 0.480 | 0.800 | -1.884 | -1.507 | [0.8 - 2.5] |
cashRatioTTM | 0.480 | 1.500 | 8.45 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.393 | -1.500 | 3.45 | -5.18 | [0 - 0.6] |
interestCoverageTTM | 5.00 | 1.000 | 9.26 | 9.26 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.348 | 2.00 | 9.88 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.130 | 2.00 | 9.93 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.937 | -1.500 | 6.25 | -9.38 | [0 - 2.5] |
grossProfitMarginTTM | 0.378 | 1.000 | 7.03 | 7.03 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.112 | 1.000 | 9.77 | 9.77 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.108 | 1.000 | -0.511 | -0.511 | [0.2 - 2] |
assetTurnoverTTM | 0.491 | 0.800 | -0.0576 | -0.0460 | [0.5 - 2] |
Total Score | 9.57 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 39.63 | 1.000 | 6.10 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0679 | 2.50 | -0.229 | -0.535 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.130 | 2.00 | 9.96 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.348 | 2.00 | 9.88 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.333 | 1.500 | 6.67 | -6.67 | [0 - 1] |
pegRatioTTM | -48.27 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0863 | 1.000 | -0.342 | 0 | [0.1 - 0.5] |
Total Score | 2.52 |
Clinigen Group PLC
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。